Evonetix Places First DNA Synthesis Development Platform at Imperial College London; External Placement Marks Key Milestone in Development of Evonetix’s Benchtop DNA Synthesis Technology, in Preparation for Customer Use and Commercialization

On October 4, 2023, EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London. This is the Company’s first platform to be installed in an external scientific setting; a significant milestone as it continues to optimize its gene synthesis technology in preparation for customer use and commercialization. The platform has been placed in labs led by Dr. Marko Storch, Head of Synthetic Biology and Automation, London Biofoundry, Imperial College London, and Professor Paul Freemont, Head of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London. The installation of this platform follows the delivery of Evonetix’s chip-synthesized DNA for evaluation to Dr. Jenny Molloy, Co-Chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge earlier this year.

Login Or Register To Read Full Story